Asia Pacific Academy of Science Pte. Ltd. (APACSCI) specializes in international journal publishing. APACSCI adopts the open access publishing model and provides an important communication bridge for academic groups whose interest fields include engineering, technology, medicine, computer, mathematics, agriculture and forestry, and environment.
MMP-9 AS PROGNOSTIC MARKER IN MELANOMA PATIENTS WITH CIRCULATING-FREE DNA BRAF V600E MUTATION
Vol 32, Issue 4S1, 2018
Abstract
Despite the revolution in the field of melanoma treatment with the introduction of novel therapies(immunotherapy and target therapy), there is still a percentage of melanoma patients that oftenexperiences drug-resistance and therapeutic failure. The early recognition of therapeutic failure, bythe identification of new biomarkers of therapeutic response, is the main challenge of medical oncologyin order to personalize the therapeutic strategies and avoid the toxicity of ineffective treatments. Thecirculating-free DNA BRAFV600E mutation was proposed as a marker of therapeutic response. However,it cannot be revealed in all melanoma patients with this mutation, detected in tumour biopsy specimens.Therefore, there is a need to identify new prognostic biomarkers. Matrix Metalloproteinase-9 (MMP-9)could be one of them since its role in tumour invasiveness have been demonstrated.
References
Supporting Agencies
Copyright (c) 2018
This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
Medical Genetics, University of Torino Medical School, Italy
Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy